[1] Furth N, Aylon Y. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway[J]. Cell Death Differ, 2017, 24(9): 1488-1501.
[2] Yi J, Lu L, Yanger K, et al. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ[J]. Hepatology, 2016, 64(5): 1757-1772.
[3] Verma A, Jing-Song F, Finch-Edmondson ML, et al. Biophysical studies and NMR structure of YAP2 WW domain - LATS1 PPxY motif complexes reveal the basis of their interaction[J]. Oncotarget, 2018, 9(8): 8068-8080.
[4] Zhang C, Wang F, Xie Z, et al. Dysregulation of YAP by the Hippo pathway is involved in intervertebral disc degeneration, cell contact inhibition, and cell senescence[J]. Oncotarget, 2017, 9(2): 2175-2192.
[5] Man QW, Ma YQ, Liu JY, et al. Expression of YAP/TAZ in keratocystic odontogenic tumors and its possible association with proliferative behavior[J]. Bio Med Res Int, 2017, 2017: 1-7.
[6] Kim M, Kim M, Park S-J, et al. Role of angiomotin-like 2 mono-ubiquitination on YAP inhibition[J]. EMBO Rep, 2016, 17(1): 64–78.
[7] Kim W, Cho YS, Wang X, et al. Hippo signaling is intrinsically regulated during cell cycle progression by APC/CCdh1[J]. Proc Natl Acad Sci USA, 2019, 116(19): 9423-9432.
[8] 章艳茹, 于珍, 邱录贵. LATS2基因与肿瘤[J]. 国际肿瘤学杂志, 2013, 40(1): 3-5.
[9] Wang X, Huai G, Wang HL, et al. Mutual regulation of the Hippo/Wnt/LPA/TGFβ signaling pathways and their roles in glaucoma (Review)[J]. Int J Mol Med, 2018, 41(3): 1201-1212.
[10] Shen LL, Wen J, Zhao TT, et al. A genetic variant in large tumor suppressor kinase 2 of Hippo signaling pathway contributes to prognosis of hepatocellular carcinoma[J]. Onco Targets Ther, 2016, 9: 1945-1951.
[11] 马立聪, 田旭阳, 贾彦彬. 大肿瘤抑制激酶在肿瘤中的研究进展[J]. 肿瘤研究与临床, 2018, 30(8): 568-572.
[12] 张慧玲, 郑华川, 赵爽, 等. 过表达LATS1抑制头颈部鳞状细胞癌B88细胞增殖和侵袭及其临床意义[J]. 肿瘤, 2019, 39(1): 1-9.
[13] 张雯, 刘双玥, 安红梅, 等. LATS1在宫颈癌中的表达及其生物学特性的实验研究[J]. 现代妇产科进展, 2017, 26(4): 258-261, 265.
[14] Ma LC, Tian XY, Gao F, et al. Association analysis between SNPs in LATS1 and LATS2 and non-cardia gastric cancer[J]. BMC Gastroenterol, 2020, 20(1): 155.
[15] Moleirinho S, Hoxha S, Mandati V, et al. Regulation of localization and function of the transcriptional co-activator YAP by angiomotin[J]. Elife, 2017, 6: e23966
[16] Mana-Capelli S, McCollum D. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling[J]. J Biol Chem, 2018, 293(47): 18230-18241.
[17] Yeung B, Khanal P, Mehta V, et al. Identification of Cdk1-LATS-Pin1 as a novel signaling axis in anti-tubulin drug response of cancer cells[J]. Mol Cancer Res, 2018, 16(6): 1035-1045.
[18] Lee DH, Park JO, Kim TS, et al. LATS-YAP/TAZ controls lineage specification by regulating TGFβ signaling and Hnf4α expression during liver development[J]. Nat Commun, 2016, 7: 11961.
[19] Li J, Chen X, Ding X, et al. LATS2 suppresses oncogenic wnt signaling by disrupting β-catenin/BCL9 interaction[J]. Cell Rep, 2020, 5(6): 1650-1663.
[20] Kim NG, Gumbiner BM. Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway[J]. J Cell Biol, 2015, 210(3): 503-515.
[21] Yao F, Zhou WZ, Zhong CX, et al. LATS2 inhibits the activity of NF-κ B signaling by disrupting the interaction between TAK1 and IKKβ[J]. Tumour Biol, 2015, 36(10): 7873-7879.
[22] 刘鑫慧, 杨清. LIMK的研究进展[J]. 现代肿瘤医学, 2018, 26(1): 137-141.
[23] Bolgioni AF, Ganem NJ. The interplay between centrosomes and the Hippo tumor suppressor pathway[J]. Chromosome Res, 2016, 24(1): 93-104.
[24] Watt KI, Harvey KF, Gregorevic P. Regulation of tissue growth by the mammalian hippo signaling pathway[J]. Front Physiol, 2017, 8: 942.
[25] Ma B, Chen Y, Chen L, et al. Hypoxia regulates Hippo signaling through the SIAH2 ubiquitin E3 ligase[J]. Nat Cell Biol, 2015, 17(1): 95-103.
[26] Zhang Y, Del Re DP. A growing role for the Hippo signaling pathway in the heart[J]. J Mol Med (Berl), 2017, 95(5): 465-472.
[27] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[28] Driskill JH, Pan D. The Hippo pathway in liver homeostasis and pathophysiology[J]. Annu Rev Pathol, 2021, 16: 299-322.
[29] 肖维, 李泉, 张洪昌, 等. miR-96与miR-103在肝癌组织中的表达及其与预后的关系[J]. 肿瘤防治研究, 2020, 47(6): 446-450.
[30] 李明, 李庆军, 周进学, 等. miR-103通过抑制LATS2促进肝细胞肝癌侵袭转移的机制[J]. 肝胆外科杂志, 2017, 25(4): 312-316.
[31] Yang XY, Yu J, Yin J, et al. MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2[J]. Pharmazie, 2012, 67(7): 645-651.
[32] 陈小龙, 何枫, 吴庆琛. LATS1在食管鳞癌中的表达及启动子甲基化状态研究[J]. 基因组学与应用生物学, 2018, 37(6): 2751-2756.
[33] 罗骏, 王聪懿, 熊伟, 等. 过表达LATS1降低食管癌Eca109细胞增殖[J]. 基础医学与临床, 2015, 35(6): 792-796.
[34] Lee KH, Goan YG, Hsiao M, et al. MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer[J]. Exp Cell Res, 2009, 315(15): 2529-2538.
[35] Zhou GX, Li XY, Zhang Q, et al. Effects of the hippo signaling pathway in human gastric cancer[J]. Asian Pac J Cancer Prev, 2013, 14(9): 5199-5205.
[36] Choi W, Kim J, Park J, et al. YAP/TAZ initiates gastric tumorigenesis via upregulation of MYC[J]. Cancer Res, 2018, 78(12): 3306-3320.
[37] Li L, Zhao JG, Huang SS, et al. MiR-93-5p promotes gastric cancer-cell progression via inactivation of the Hippo signaling pathway[J]. Gene, 2018, 641: 240-247.
[38] 黄耀凭, 杨凤, 周天华, 等. Hippo信号通路及其在消化系统肿瘤中的作用研究进展[J]. 浙江大学学报(医学版), 2020, 49(1): 35-43.
[39] Yamashita S, Yamamoto H, Mimori K, et a1. MicroRNA-372 is associated with poor prognosis in colorectal cancer[J]. Oncology, 2012, 82(4): 205-212.
[40] Ragusa M, Statello L, Maugeri M, et al. Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors[J]. J Mol Med (Berl), 2012, 90(12): 1421-1438.
[41] Lee HJ, Pham T, Chang MT, et al. The tumor suppressor BAP1 regulates the Hippo pathway in pancreatic ductal adenocarcinoma[J]. Cancer Res, 2020, 80(8): 1656-1668.
[42] Hein AL, Brandquist ND, Ouellette CY, et al. PR55α regulatory subunit of PP2A inhibits the MOB1/LATS cascade and activates YAP in pancreatic cancer cells[J]. Oncogenesis, 2019, 8(11): 63.
[43] Han YY. Analysis of the role of the Hippo pathway in cancer[J]. J Transl Med, 2019, 17(1): 116.
[44] Huang YP, Yang F, Zhou TH, et al. Emerging roles of Hippo signaling pathway in gastrointestinal cancers and its molecular mechanisms[J]. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2020, 49(1): 35-43.
[45] 刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.
